美国炎症性肠病新近共识和指南述要
New insights into inflammatory bowel disease management from the latest American guidelines
魏娟 1汪芳裕1
作者信息
- 1. 东部战区总医院南京大学医学院附属金陵医院消化内科(南京,210007)
- 折叠
摘要
炎症性肠病(inflammatory bowel disease,IBD)是一种特发性累及胃肠道的慢性炎症性疾病,由多种病因引起,其发病机制尚未完全明了,有终生复发倾向,且缺乏特效的治疗方法,常需多学科共同诊治和关怀.随着IBD相关的分子基础研究及临床研究快速发展,新的治疗药物如生物制剂、小分子药物快速迭代更新.笔者对美国胃肠病学会近年发表的相关IBD诊治指南及共识进行扼要介绍和述评,以期为IBD的规范化诊治提供帮助.
Abstract
Inflammatory bowel disease(IBD)is an idiopathic chronic inflammatory disease involving the gas-trointestinal tract,with many underlying causes.The etiology of IBD remains largely unknown.IBD has a tenden-cy of lifelong recurrence,lacking of optimal treatments and requiring multi-disciplinary diagnosis and care.With the rapid development of molecular basic research and clinical research related to IBD,new therapeutic drugs such as biologics and small molecule drugs are rapidly updated.In this review,the author summarizes the current sta-tus and progress of drug therapy for IBD based on guidelines or consensus from American Gastroenterological As-sociation recent years,in order to provide help for the standardized management of IBD in China.
关键词
炎症性肠病/溃疡性结肠炎/克罗恩病/治疗目标/生物制剂/小分子药物Key words
inflammatory bowel disease/ulcerative colitis/Crohn's disease/treating to target/biologics/small molecule drugs引用本文复制引用
出版年
2024
NETL
NSTL
万方数据